Coherus Biosciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Ali J. Satvat received 30,000 restricted stock units and 60,000 stock options as part of annual compensation for service on the board.
NASDAQ
Director Rita A. Karachun was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology, Inc.
NASDAQ
Coherus Oncology director Lee Nisley Newcomer was granted 30,000 restricted stock units and 60,000 stock options.
NASDAQ
Director Michael Lee Ryan was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology, Inc.
NASDAQ
Director Jill O'Donnell-Tormey was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology.
NASDAQ
Coherus BioSciences director Mats Wahlstrom was granted 30,000 restricted stock units and 60,000 stock options.
NASDAQ
Director Charles W. Newton was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology, Inc.
NASDAQ
Coherus Oncology CFO Bryan J. McMichael completed an option repricing program approved by stockholders on May 29, 2026.
NASDAQ
Coherus Oncology CEO Dennis M. Lanfear completed a comprehensive repricing of existing stock options to $1.59 per share following stockholder approval.
NASDAQ
Coherus Oncology's President & CEO, Dennis M. Lanfear, acquired 375,000 restricted stock units and 750,000 stock options on January 23, 2026.
NASDAQ
Coherus Oncology's Chief Financial Officer, Bryan J. McMichael, was granted 112,500 restricted stock units and options to purchase 225,000 shares of common stock.
NASDAQ
Coherus Oncology's CFO, Bryan J. McMichael, reported the disposition of 1,715 shares of common stock to cover tax liabilities related to RSU vesting.
NASDAQ
Coherus Oncology's President & CEO, Dennis M. Lanfear, reported the withholding of 11,839 common shares by the issuer for tax liabilities related to restricted stock unit vesting.
NASDAQ
Coherus Oncology, Inc. Director Jill O'Donnell-Tormey was granted 112,000 stock options with an exercise price of $0.7904 per share, vesting fully on June 11, 2026.
NASDAQ
Coherus Oncology, Inc. Director Lee Nisley Newcomer was granted 112,000 stock options with an exercise price of $0.7904, vesting over one year.
NASDAQ
Coherus Oncology, Inc. Director Mats Wahlstrom was granted 112,000 stock options with an exercise price of $0.7904, vesting one year from June 11, 2025.
NASDAQ
Coherus Oncology, Inc. Director Michael Lee Ryan was granted 112,000 stock options with an exercise price of $0.7904, vesting one year from June 11, 2025.
NASDAQ
Coherus Oncology, Inc. Director Rita A. Karachun was granted 112,000 stock options with an exercise price of $0.7904, vesting fully on June 11, 2026.
NASDAQ
Coherus Oncology, Inc. Director Georgia Erbez was granted 112,000 stock options with an exercise price of $0.7904, which will fully vest on June 11, 2026.
NASDAQ
Coherus Oncology, Inc. Director Charles W. Newton was granted 112,000 stock options with an exercise price of $0.7904, vesting fully on June 11, 2026.
NASDAQ
Coherus Oncology, Inc. Director Ali J. Satvat was granted 112,000 stock options with an exercise price of $0.7904, vesting fully on June 11, 2026.
NASDAQ
A director at Coherus BioSciences, Mats Wahlstrom, has sold all 99,988 shares of his common stock in the company for tax planning purposes, ceasing all beneficial ownership.
NASDAQ
Bryan J. McMichael, CFO of Coherus BioSciences, acquired 200,000 stock options on May 7, 2025, according to a Form 4 filing with the SEC.
NASDAQ
Dennis M. Lanfear, President & CEO of Coherus BioSciences, Inc., was granted 375,000 stock options on May 7, 2025, according to a Form 4 filing with the SEC.
NASDAQ
Form 4: Coherus BioSciences CFO Reports Stock Transaction Following Vesting of Restricted Stock Units
Coherus BioSciences' Chief Financial Officer, Bryan J. McMichael, had 1,711 shares withheld to cover tax liabilities related to the vesting of restricted stock units.
NASDAQ
Paul Reider, Chief Commercial Officer of Coherus BioSciences, sold 4,858 shares to cover tax liabilities related to vesting restricted stock units.
NASDAQ
Coherus BioSciences CEO Dennis Lanfear had 11,810 shares withheld to cover tax liabilities related to vesting restricted stock units.
NASDAQ
Coherus BioSciences CEO, Dennis M. Lanfear, was granted 575,000 stock options on January 10, 2025, according to a recent SEC filing.
NASDAQ
Bryan J. McMichael, CFO of Coherus BioSciences, reports the withholding of shares to cover tax liabilities related to vesting restricted stock units.
NASDAQ
Coherus BioSciences CEO Dennis Lanfear disposed of 11,810 shares to cover tax obligations related to vesting restricted stock units.